Translation to humans of our in vivo CAR T cell generation strategy is also encouraged by a recent clinical Phase I trial for treatment of T cell lymphoma patients demonstrating that ex vivo generated anti-CD4 CAR T cells resulted in complete remission in the first three patients treated without development of severe side effects [42]. This evidence concerns the gene CD4 and T-cell non-Hodgkin lymphoma.